Linking an insect enzyme to hypertension: Angiotensin II-epoxide hydrolase interactions

Kidney International

Volumn 77, Issue 2, 2010, Pages 88-92

  Ai, Ding ^a,b   Shyy, John Y J ^c   Zhu, Yi ^a,b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiotensin II; Cardiac hypertrophy; Endothelial cells; Hypertension; Soluble epoxide hydrolase

Indexed keywords

ANGIOTENSIN II; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID;

BLOOD PRESSURE REGULATION; DOWN REGULATION; ENDOTHELIUM CELL; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; INSECT; NONHUMAN; PRIORITY JOURNAL; SHEAR STRESS; SHORT SURVEY; STIMULATION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR ENDOTHELIUM;

EID: 73349130413     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.349     Document Type: Short Survey

References (20)

1. Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog Lipid Res 2005; 44: 1-5.
2. Hu S, Kim HS. Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur J Pharmacol 1993; 230: 215-221.
3. Node K, Huo Y, Ruan X et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-1279.
4. Ai D, Pang W, Li N et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106: 564-569.
5. Yu Z, Xu F, Huse LM et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87: 992-998.
6. Zhao X, Yamamoto T, Newman JW et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004; 15: 1244-1253.
7. Imig JD, Zhao X, Capdevila JH et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 2002; 39: 690-694.
8. Jung O, Brandes RP, Kim IH et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 2005; 45: 759-765.
9. Imig JD, Zhao X, Zaharis CZ et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005; 46: 975-981.
10. Wang H, Lin L, Jiang J et al. Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther 2003; 307: 753-764.
11. Hercule HC, Schunck WH, Gross V et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler Thromb Vasc Biol 2009; 29: 54-60.
12. Olearczyk JJ, Quigley JE, Mitchell BC et al. Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (London) 2009; 116: 61-70.
13. Ai D, Fu Y, Guo D et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 2007; 104: 9018-9023.
14. Monti J, Fischer J, Paskas S et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet 2008; 40: 529-537.
15. Liu Y, Zhang Y, Schmelzer K et al. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci USA 2005; 102: 16747-16752.
16. Liu Y, Zhu Y, Rannou F et al. Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. Circulation 2004; 110: 1128-1133.
17. Ulu A, Davis BB, Tsai HJ et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 2008; 52: 314-323.
18. Chiamvimonvat N, Ho CM, Tsai HJ et al. The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 2007; 50: 225-237.
19. Xu D, Li N, He Y et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 2006; 103: 18733-18738.
20. Batchu SN, Law E, Brocks DR et al. Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. J Mol Cell Cardiol 2009; 46: 67-74.